Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,066.18 +55.58 (+1.11%) Dow
38,466.44 +226.46 (+0.59%) Nasdaq
15,686.26 +234.95 (+1.52%) Bitcoin USD
66,678.49 +844.14 (+1.28%) CMC Crypto 200
1,437.20 +22.44 (+1.59%)
ABBV Jun 2024 185.000 put
| Previous close | 19.50 |
| Open | 19.50 |
| Bid | 15.50 |
| Ask | 16.25 |
| Strike | 185.00 |
| Expiry date | 2024-06-21 |
| Day's range | 19.50 - 19.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 15 |
ZacksGear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
PR NewswireAllergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics loyalty rewards program. Beginning today, consumers—including existing patients and those who are considering aesthetic treatment—can apply for a chance to be included in future brand campaigns. The first Allergan Aesthetics open casting call for BO
ZacksAbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
